(Q44061379)

29 November 2017

title

Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration (English)

1 reference

29 November 2017

1 reference

Anthony S Basile

1

1 reference

29 November 2017

Matt Hutmacher

2

1 reference

29 November 2017

Dana Nickens

3

1 reference

29 November 2017

Jace Nielsen

4

1 reference

29 November 2017

Ken Kowalski

5

1 reference

29 November 2017

Lloyd Whitfield

6

1 reference

29 November 2017

Oishi Masayo

7

1 reference

29 November 2017

Masami Nakane

8

1 reference

29 November 2017

publication date

23 September 2011

1 reference

The Journal of Clinical Pharmacology

29 November 2017

published in

1 reference

29 November 2017

volume

52

1 reference

29 November 2017

issue

8

1 reference

29 November 2017

page(s)

1186-1199

1 reference

The epidemiology of age-related macular degeneration

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Prevalence of age-related macular degeneration in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Angiogenesis in cancer and other diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Increased expression of angiogenic growth factors in age-related maculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Aptamers: an emerging class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Pharmacokinetics and biodistribution of novel aptamer compositions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Systemic absorption of ocularly administered enkephalinamide and inulin in the albino rabbit: extent, pathways, and vehicle effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Likelihood based approaches to handling data below the quantification limit using NONMEM VI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Ways to fit a PK model with some data below the quantification limit

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011412961

21 January 2018

Identifiers

DOI

10.1177/0091270011412961

1 reference

29 November 2017

1 reference